Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...
Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in ...
Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...
Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...
Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...
New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.
ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...
Clinical Trials Arena on MSN8d
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patientsPharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...
– Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefit in a Phase 3 trial – ...
Nat Clin Pract Oncol. 2008;5(9):531-542. The authors declared no competing interests. Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback